Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells

Nature Medicine
C D GimmiL M Nadler

Abstract

Given the plethora of well-documented breast carcinoma-associated antigens in humans including MAGE-1, -2 and -3, mutated p53, p21ras, HER-2/neu and DF3/MUC-1, coupled with evidence that humoral and cytotoxic T-cell responses against these antigens exist, the central dilemma facing tumor immunologists is why the host immune response is so inefficient. One possibility is that tumor cells themselves are either inefficient or ineffective antigen-presenting cells (APCs). The failure of tumor cells to function as APCs may be due to their inability to process and present the antigen, the absence or insufficient numbers of adhesion and costimulatory molecules or, potentially, the secretion of inhibitory cytokines. Therefore, we sought to determine whether human breast cancer cell lines could function as APCs and, if not, to identify mechanism(s) responsible for this defect. Here, we show that human breast cancer cell lines fail to present alloantigen. This defect does not reside in their inherent capacity to present antigen but rather is due to apoptosis of activated T cells induced by exposure to the breast carcinoma-associated mucin antigen, DF3/MUC1. These results support the hypothesis that DF3/MUC1 may contribute to the paucity o...Continue Reading

References

Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C D GimmiL M Nadler
Jun 15, 1989·International Journal of Cancer. Journal International Du Cancer·A GirlingJ Taylor-Papadimitriou
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D L BarndO J Finn
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J SiddiquiD Kufe

❮ Previous
Next ❯

Citations

Mar 22, 2002·The Lancet Oncology·R Midgley, D Kerr
Apr 30, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E M H A de Kleijn, C J A Punt
Jun 5, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M GionE Marubini
Nov 22, 1997·Current Opinion in Immunology·B J Van den Eynde, P van der Bruggen
Nov 9, 2011·Breast Cancer Research and Treatment·M T SandriM Colleoni
May 3, 2005·Cancer Immunology, Immunotherapy : CII·J WiereckyP Brossart
Jul 11, 2007·Cancer Immunology, Immunotherapy : CII·Susan F SlovinHoward I Scher
Nov 22, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·P Nguyen Van BinhH Thien Duc
May 28, 2011·Thyroid : Official Journal of the American Thyroid Association·Kee-Hyun NamCheong Soo Park
May 7, 1999·International Journal of Immunopharmacology·J W Hadden
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Su-hu LiuWang-Gang Zhang
Nov 6, 2007·Cancer Biotherapy & Radiopharmaceuticals·Zheng LiJie Ma
Nov 4, 2000·Expert Opinion on Investigational Drugs·H M Fathallah-ShaykhA I Kafrouni
Jul 27, 2005·British Journal of Haematology·S J Harrison, G Cook
Aug 10, 2007·British Journal of Haematology·Guy PrattPaul Moss
Jan 10, 2013·Scandinavian Journal of Immunology·A Anandkumar, H Devaraj
Oct 20, 1999·Blood Reviews·G Cook, J D Campbell
Jun 14, 2014·Biochemical and Biophysical Research Communications·Yukiko TomiokaEtsuro Ono
Sep 23, 2008·Expert Opinion on Pharmacotherapy·Peng H Tan, Amrit S Lota
Sep 7, 2016·Nucleic Acids Research·Xiaoping LiuLuonan Chen
Feb 19, 1997·Journal of the National Cancer Institute·R G Fenton, D L Longo
Nov 24, 2006·Journal of Dental Research·A JewettN A Cacalano
Nov 14, 1997·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Y CaoU Karsten
Mar 21, 1998·Nature Medicine·A N Houghton, K O Lloyd
May 14, 1998·International Journal of Cancer. Journal International Du Cancer·T SuwaK Imai
Nov 5, 1999·The Journal of Pathology·M MüschenD Häussinger
Dec 5, 2000·International Journal of Cancer. Journal International Du Cancer·T IwasakiM Okada
Jan 19, 2018·International Journal of Molecular Sciences·Etsuro Ono, Toshimitsu Uede
Dec 19, 2003·Nature Reviews. Cancer·Michael A Hollingsworth, Benjamin J Swanson
Dec 17, 2003·The Journal of Biological Chemistry·Armin RumpAtsushi Miyajima
Oct 15, 1998·Nature Medicine·V A BoussiotisL M Nadler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis